Saphetor SA raises CHF 1.2 million in seed financing round18.02.2016 09:10
Saphetor SA, a Swiss precision medicine company working at the cutting edge of clinically meaningful genome-scale analysis based on Next Generation Sequencing (NGS), announced that it successfully completed a CHF 1.2 million seed financing round from a group of undisclosed investors.
Saphetor develops software and sophisticated analytical processes, using proprietary algorithms and trade secret know-how to identify genetic variants with greater accuracy and to give its clients access to seamlessly integrated data from a rapidly growing collection of genetic databases. To date, Saphetor has already aggregated 20 leading databases, representing more than 10 billion genetic variant annotations. Saphetor’s competitive advantage is its unique ability to combine data integration with annotation and interpretation in an interface that is intuitive and easy to navigate.
Andreas Massouras, CEO of Saphetor, said: “We are delighted with the closing of the seed financing round. The proceeds will allow us to further develop our advanced NGS analysis capabilities, and expand our network of commercial and research collaborations in Europe and beyond well into 2017. We have built a decision support platform that offers information of unprecedented depth and detail to professionals in clinical genetics research and medical diagnostics to help them make informed decisions, and that is intuitive and easy to use.”
Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment.